Demographics and clinical characteristics at baseline of patients with csEVH in the 302 study
| Variable . | Eculizumab (n = 20) . | Ravulizumab (n = 19) . |
|---|---|---|
| Age at PNH diagnosis, mean ± SD (range), y | 44.5 ± 14.3 (22-74) | 36.8 ± 16.34 (6-65) |
| Age at first eculizumab infusion, mean ± SD (range), y | 50.6 ± 14.2 (24-74) | 42.9 ± 15.1 (19-68) |
| LDH, mean ± SD (range), U/L | 243.5 ± 50.9 (153.3-365.5) | 246.7 ± 51.1 (146.0-330.5) |
| PNH clone size, mean ± SD (range), n | ||
| RBC type II | 19 10.4 ± 17.9 (0.1-74.4) | 17 8.0 ± 8.5 (0.5-29.3) |
| RBC type III | 20 61.9 ± 29.2 (1.2-99.2) | 19 66.1 ± 20.3 (26.1-98.8) |
| Total RBC | 19 71.7 ± 24.4 (26.8-99.6) | 17 76.0 ± 23.6 (26.6-99.6) |
| Granulocytes | 20 93.6 ± 7.2 (73.1-99.6) | 19 95.9 ± 6.4 (71.4-99.9) |
| Monocytes | 20 94.9 ± 7.4 (68.6-99.6) | 19 96.1 ± 6.7 (70.3-99.9) |
| Variable . | Eculizumab (n = 20) . | Ravulizumab (n = 19) . |
|---|---|---|
| Age at PNH diagnosis, mean ± SD (range), y | 44.5 ± 14.3 (22-74) | 36.8 ± 16.34 (6-65) |
| Age at first eculizumab infusion, mean ± SD (range), y | 50.6 ± 14.2 (24-74) | 42.9 ± 15.1 (19-68) |
| LDH, mean ± SD (range), U/L | 243.5 ± 50.9 (153.3-365.5) | 246.7 ± 51.1 (146.0-330.5) |
| PNH clone size, mean ± SD (range), n | ||
| RBC type II | 19 10.4 ± 17.9 (0.1-74.4) | 17 8.0 ± 8.5 (0.5-29.3) |
| RBC type III | 20 61.9 ± 29.2 (1.2-99.2) | 19 66.1 ± 20.3 (26.1-98.8) |
| Total RBC | 19 71.7 ± 24.4 (26.8-99.6) | 17 76.0 ± 23.6 (26.6-99.6) |
| Granulocytes | 20 93.6 ± 7.2 (73.1-99.6) | 19 95.9 ± 6.4 (71.4-99.9) |
| Monocytes | 20 94.9 ± 7.4 (68.6-99.6) | 19 96.1 ± 6.7 (70.3-99.9) |
SD, standard deviation.